In particular, a phase II trial (NCT03931551) aimed to recruit HER2+ BC patients with gene alterations in the HRR DNA pathway (including germline deleterious mutations in BRCA1 or BRCA2 genes) in order to evaluate the efficacy of the association of olaparib and trastuzumab. The gene discussed is BRCA1; the disease is breast cancer.